Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P42226: Variant p.Asp419Asn

Signal transducer and activator of transcription 6
Gene: STAT6
Feedback?
Variant information Variant position: help 419 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Aspartate (D) to Asparagine (N) at position 419 (D419N, p.Asp419Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In HIES6; likely pathogenic; increased DNA-binding transcription factor activity; increased STAT6 phosphorylation at baseline and after stimulation with IL4. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 419 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 847 The length of the canonical sequence.
Location on the sequence: help LPIQLQALSLPLVVIVHGNQ D NNAKATILWDNAFSEMDRVP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         LPIQLQALSLPLVVIVHGNQDNNAKATILWDNAFSEMDRVP

Mouse                         LLIQLQALSLPLVVIVHGNQDNNAKATILWDNAFSEMDRVP
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 847 Signal transducer and activator of transcription 6



Literature citations
Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease.
Sharma M.; Leung D.; Momenilandi M.; Jones L.C.W.; Pacillo L.; James A.E.; Murrell J.R.; Delafontaine S.; Maimaris J.; Vaseghi-Shanjani M.; Del Bel K.L.; Lu H.Y.; Chua G.T.; Di Cesare S.; Fornes O.; Liu Z.; Di Matteo G.; Fu M.P.; Amodio D.; Tam I.Y.S.; Chan G.S.W.; Sharma A.A.; Dalmann J.; van der Lee R.; Blanchard-Rohner G.; Lin S.; Philippot Q.; Richmond P.A.; Lee J.J.; Matthews A.; Seear M.; Turvey A.K.; Philips R.L.; Brown-Whitehorn T.F.; Gray C.J.; Izumi K.; Treat J.R.; Wood K.H.; Lack J.; Khleborodova A.; Niemela J.E.; Yang X.; Liang R.; Kui L.; Wong C.S.M.; Poon G.W.K.; Hoischen A.; van der Made C.I.; Yang J.; Chan K.W.; Rosa Duque J.S.D.; Lee P.P.W.; Ho M.H.K.; Chung B.H.Y.; Le H.T.M.; Yang W.; Rohani P.; Fouladvand A.; Rokni-Zadeh H.; Changi-Ashtiani M.; Miryounesi M.; Puel A.; Shahrooei M.; Finocchi A.; Rossi P.; Rivalta B.; Cifaldi C.; Novelli A.; Passarelli C.; Arasi S.; Bullens D.; Sauer K.; Claeys T.; Biggs C.M.; Morris E.C.; Rosenzweig S.D.; O'Shea J.J.; Wasserman W.W.; Bedford H.M.; van Karnebeek C.D.M.; Palma P.; Burns S.O.; Meyts I.; Casanova J.L.; Lyons J.J.; Parvaneh N.; Nguyen A.T.V.; Cancrini C.; Heimall J.; Ahmed H.; McKinnon M.L.; Lau Y.L.; Beziat V.; Turvey S.E.;
J. Exp. Med. 220:0-0(2023)
Cited for: VARIANTS HIES6 GLN-382; GLY-419; TYR-419; HIS-419; ASN-419; ALA-419; HIS-519; ARG-595 AND ARG-643; CHARACTERIZATION OF VARIANTS HIES6 GLN-382; GLY-419; TYR-419; ASN-419; HIS-419; ALA-419; HIS-519; ARG-595 AND ARG-643; FUNCTION; CHARACTERIZATION OF VARIANT VAL-321; MUTAGENESIS OF TYR-641;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.